Recent Articles

• 
  Vaccine / Biotech

  ‘Stronger With Less’ Korea Research Develops High-Efficiency Vaccine Platform

  Schematic diagram of a next-generation low-dose mRNA vaccine platform. Provided by the Korea Research Institute of Bioscience and Biotechnology (KRIBB) The Korea Research Institute of Bioscience and Biotechnology (KRIBB) announced on the 7th that it has developed a design method for a next-generatio

  2026.04.07
• 
  Medical / Drug Development

  SK Biopharm Unveils Radiopharmaceutical at World’s Largest Cancer Meeting

  SK Biopharm announced on the 6th that it will present preclinical research results for its radiopharmaceutical (RPT) therapeutic candidate “SKL35501” and imaging diagnostic agent “SKL35502” at the “2026 American Association for Cancer Research (AACR) Annual Meeting,” to be held in San Diego, Califor

  2026.04.06
• 
  Biopharma

  LG Chem Licenses Japan’s Top Endometriosis Drug

  Product image of Dinagest, an endometriosis treatment by Mochida Pharmaceutical in Japan. Provided by Mochida Pharmaceutical LG Chem is strengthening its women’s health portfolio by introducing Japan’s No. 1 endometriosis treatment (based on the Japanese dienogest ingredient market).LG Chem announce

  2026.04.03
• 
  MOU / Drug Development

  SK Biopharm, Seoul Bio Hub Partner to Mentor Startups

  SK Biopharmaceuticals and Seoul Bio Hub hold a ceremony to sign an agreement and take a commemorative photo. (From left) Kim Hyun-woo, Head of Seoul Bio Hub Center; Kim Sung-young, CEO of Three Brooks Therapeutics; Kang Hae-ra, Director of the Advanced Industry Division at the Seoul Metropolitan Gov

  2026.04.03
• 
  Global Business

  Eating to Lose Weight: Obesity Pill Wars

  The “oral obesity drug” race has begun. According to Reuters and other foreign media on the 2nd (local time), the US Food and Drug Administration (FDA) on the 1st approved Eli Lilly’s oral obesity treatment “Poundayo (orforglipron).” Following Novo Nordisk’s launch of oral Wegovy at the beginning of

  2026.04.03
• 
  AI Healthcare

  Holmes AI Selected for Nvidia Startup Support Program

  Medical AI platform specialist Holmes AI (홈즈AI) announced on the 2nd that it will join “NVIDIA Inception,” NVIDIA’s global startup support program.NVIDIA Inception is a program that discovers and nurtures startups with innovation in the fields of artificial intelligence (AI), data science, and high-

  2026.04.02
• 
  Medical / Clinical Case

  Celltrion Proves Zympentra Dose Increase Effective

  Celltrion Second Plant. Provided by Celltrion Celltrion announced on the 2nd that a paper containing the post-hoc analysis results from the global Phase 3 clinical trial of “Zympentra (Remsima SC),” the world’s only subcutaneous (SC) formulation of infliximab, has been published in the latest issue

  2026.04.02
• 
  Pharmaceutical R&D

  LG Chem to Develop Novel Cancer Drug, Licenses FMC-220

  LG Chem CI. Provided by LG Chem LG Chem is moving to develop an innovative anticancer drug targeting an unaddressed target by introducing a new drug candidate.LG Chem announced on the 1st that it has signed an exclusive global license agreement for development and commercialization of the anticancer

  2026.04.02
• 
  Biopharma

  Daewoong Pharma Launches Low-Dose Statin Combo Drug

  Daewoong Pharmaceutical headquarters. Courtesy of Daewoong Pharmaceutical Daewoong Pharmaceutical announced on the 1st that it has launched the dyslipidemia combination drug “BaroEzet Tablet” (pitavastatin/ezetimibe combination) and has begun full-scale sales. BaroEzet Tablet is a new low-dose combi

  2026.04.01
• 
  Medical / Drug Development

  SK Biopharm Seeks US FDA Nod for Liquid Cenobamate to Aid Patients With Swallowing Issues

  SK Biopharmaceuticals announced on the 1st that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an oral suspension formulation of cenobamate, its innovative anti-seizure medication for epilepsy, marketed in the United States under the brand name XCOPR

  2026.04.01